Signals, Powered By EquityPandit
Zydus Cadila receives final approval to market Nystatin ointment and Omeprazoleand Sodium Bicarbonate capsule, from the US health regulator.
The company received approval to market Nystatin Ointment USP, 1,00,000 units per gram. Nystatin ointment is used to treat fungal infections. It has also received approval to market Omeprazoleand Sodium Bicarbonate Capsules, 20 mg/1100 mg and 40 mg/1100 mg, which is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers).
Further, the drug will be manufactured at the group’s Topical manufacturing facility at Moraiya, Ahemdabad.
